HISTORY OF Psilocybin/Psilocin

---

Psilocybin, the active compound in psychedelic mushrooms, was discovered and isolated by Swiss chemist Albert Hofmann in 1958. 

Early research began to explore the pharmacological effects of psilocybin on human subjects, often conducted by scientists such as Timothy Leary and Richard Alpert. 

Psilocybin gained popularity during the counterculture movement of the 1960s, leading to an increase in recreational use. 

Researchers, including Walter Pahnke, conducted studies on the potential therapeutic benefits of psilocybin, particularly in the treatment of anxiety and end-of-life distress. 

As a result of concerns about the misuse of psychedelic substances, including psilocybin, regulatory restrictions were imposed in the early 1970s. This limited research opportunities for several decades. 

The study of psychedelics, including psilocybin, largely stagnated during this period due to legal and regulatory challenges. 

Towards the end of the 20th century and the beginning of the 21st century, there was a renewed interest in studying the therapeutic potential of psilocybin. 

Researchers conducted pilot studies exploring the use of psilocybin in the treatment of anxiety, depression, and addiction. Promising results were observed, but larger-scale trials were limited. 

The 2010s saw an increase in well-designed clinical trials exploring the effects of psilocybin-assisted therapy on various mental health conditions. 

 Landmark studies, such as those conducted by institutions like Johns Hopkins University and Imperial College London, provided evidence of the efficacy of psilocybin in reducing symptoms of depression, anxiety, and addiction. 

Some regions and countries began to decriminalize or consider decriminalizing the use of psilocybin, allowing for more research opportunities. 

The decade marked a further expansion of research into psilocybin's therapeutic potential, with ongoing trials and investigations into optimal dosages, treatment protocols, and long-term effects. 

Psilocybin received "breakthrough therapy" designation from the U.S. Food and Drug Administration (FDA) for the treatment of depression, indicating its potential as a significant advancement in treatment. 

 Ongoing research is contributing additional insights into the therapeutic applications and mechanisms of action of psilocybin. The legal access framework is being established all over the world with Canada soon to release it's formal integration of Psilocybin into both the Medical and Recreational realms - predicted to follow similar sequencing to the Cannabis Industry